LEXICON PHARMACEUTICALS, INC. (LXRX) earnings date
Mar 4, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | after close | 43 | 8-K |
| Q4 FY2024 | Thu, Mar 6, 2025 | after close | 65 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call and webcast at 8:30 am ET" exhibit |
| Q3 FY2026 | "Lexicon continues to expect topline results in the first quarter of 2027." exhibit |
| Q3 FY2026 | "Two studies of sotagliflozin will be presented at the 2026 American Heart Association (AHA) Scientific Sessions in Chicago, November 6–9, providing new insights into its potential effects on thrombus formation as well as myocardial function in HCM, including findings from living human HCM heart tissue." exhibit |
| Q3 FY2026 | "Following the results of the Phase 2 PROGRESS study in 2025, the FDA has raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo." exhibit |
| Q3 FY2026 | "Research and Development (R&D) Expenses: Research and development expenses for the third quarter of 2026 decreased to $16.2 million from $18.8 million for the corresponding period in 2025, reflecting lower external research expenses due to completion of our PROGRESS Phase 2b clinical trial in 2025 partially offset by higher SONATA-HCM Phase 3 clinical trial expense in 2026." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET" exhibit |
| Q2 FY2026 | "Lexicon continues to expect topline results in the first quarter of 2027." exhibit |
| Q2 FY2026 | "STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) is approaching the patient exposure and safety data requirements previously identified by the U.S. Food and Drug Administration (FDA) as being adequate to support a resubmission of the company's New Drug Application (NDA), which Lexicon anticipates will occur in the fourth quarter of 2026 based on current estimated timing of data collection." exhibit |
| Q2 FY2026 | "Viatris anticipates regulatory decisions in Australia and Canada and regulatory submissions in other markets in 2026." exhibit |
| Q2 FY2026 | "The Phase 1 program is expected to be completed in the first quarter of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/LXRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/LXRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/LXRX/"><img src="https://veritasdata.dev/embed/LXRX.svg" alt="LXRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/LXRX/)
Script
<script async src="https://veritasdata.dev/embed/LXRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/LXRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.